Compare Eli Lilly And Co (LLY) vs Invesco Preferred ETF (PGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Invesco Preferred ETF — how do they compare? Eli Lilly And Co trades at $1,178.99 (market cap $1.04T), while Invesco Preferred ETF trades at $10.02 (market cap $3.60B). The key difference: Eli Lilly And Co is far larger — about 288.9× Invesco Preferred ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while Invesco Preferred ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Invesco Preferred ETF for 95 Days on average.
| LLY | PGX | |
|---|---|---|
Market Cap | $1.04T | $3.60B |
Volume | 3,064,878 | 5,986,026 |
Sector | Health | — |
52-Week High | $1.28K | $11.61 |
52-Week Low | $799.57 | $9.97 |
Typical Hold Time | 93 Days | 95 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
PGX trades at $10.01, up 0.4% with bearish technical indicators showing 18 sell signals versus 3 buy signals. The stock faces resistance at $10 with RSI at neutral levels. Recent dividends of $0.06 were declared for July and September 2026, providing income potential amid technical weakness.
The outlook remains cautious with strong bearish momentum in moving averages. Investment opportunity lies in dividend yield while risks include technical breakdown below $10 support. Fundamental analysis is limited without current financial ratios, requiring updated SEC filings for proper valuation assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →
